170 related articles for article (PubMed ID: 10148312)
41. Quality assessment of platelet concentrates prepared by platelet rich plasma-platelet concentrate, buffy coat poor-platelet concentrate (BC-PC) and apheresis-PC methods.
Singh RP; Marwaha N; Malhotra P; Dash S
Asian J Transfus Sci; 2009 Jul; 3(2):86-94. PubMed ID: 20808653
[TBL] [Abstract][Full Text] [Related]
42. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
43. [Transfusion effect with platelet concentrates from various cell separators].
Kretschmer V; Planitz C; Dietrich G; Pflüger HH
Beitr Infusionsther; 1991; 28():204-8. PubMed ID: 1725620
[TBL] [Abstract][Full Text] [Related]
44. [A new multiple blood bag system with top and bottom drainage. Comparison with the conventional multiple bag system].
Pietersz RN; Dekker WJ; Reesink HW
Beitr Infusionsther; 1990; 26():60-4. PubMed ID: 1703902
[TBL] [Abstract][Full Text] [Related]
45. Improvement of the separation of blood by modification of separators Optipress and Biotrans Separator.
Kretschmer V; Tesche U; Richter P
Beitr Infusionsther; 1992; 30():112-21. PubMed ID: 1284685
[TBL] [Abstract][Full Text] [Related]
46. [A new separation protocol (DRBCP-F) for automated blood component donation with the MCS 3p cell separator for collection of leukocyte depleted erythrocyte concentrates and plasma].
Zeiler T; Kretschmer V
Beitr Infusionsther Transfusionsmed; 1997; 34():118-22. PubMed ID: 9417335
[TBL] [Abstract][Full Text] [Related]
47. Preparation of random donor leukocyte-poor platelets by cytapheresis.
Olthuis HP; Stienstra S; Puylaert CE; Verhagen CM; Bär BM
Transfus Sci; 1993 Apr; 14(2):195-7. PubMed ID: 10148612
[TBL] [Abstract][Full Text] [Related]
48. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions.
Pruss A; Kalus U; Radtke H; Koscielny J; Baumann-Baretti B; Balzer D; Dörner T; Salama A; Kiesewetter H
Transfus Apher Sci; 2004 Feb; 30(1):41-6. PubMed ID: 14746820
[TBL] [Abstract][Full Text] [Related]
49. [Blood transfusion preparations with a low leukocyte count. I. Preparation of thrombocyte concentrates from buffy coats].
Gasová Z; Turek P
Cas Lek Cesk; 1992 Dec; 131(24-25):754-5. PubMed ID: 1288879
[TBL] [Abstract][Full Text] [Related]
50. Survival in vivo of platelets stored for 48 hours in the buffycoat at 4 degrees C compared to platelet rich plasma stored at 22 degrees C.
Pietersz RN; Loos JA; Reesink HW
Blut; 1987 Apr; 54(4):201-6. PubMed ID: 3828537
[TBL] [Abstract][Full Text] [Related]
51. [Platelet-leukocyte aggregates as a marker for platelet activation in platelet concentrates].
Chakroun T; Abdelkefi S; Bouslama M; Houissa B; Zaier M; Miled A; Kortas M; Yacoub S
Transfus Clin Biol; 2008 Sep; 15(4):148-53. PubMed ID: 18760949
[TBL] [Abstract][Full Text] [Related]
52. Autologous platelet transfusion in patients receiving high-dose chemotherapy and circulating progenitor cell transplantation for stage II/III breast cancer.
Pedrazzoli P; Perotti C; Noris P; Da Prada GA; Zibera C; Battaglia M; Gibelli N; Preti P; Pavesi L; Torretta L; Balduini CL; Salvaneschi L; Robustelli della Cuna G
Haematologica; 1998 Aug; 83(8):718-23. PubMed ID: 9793256
[TBL] [Abstract][Full Text] [Related]
53. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions.
Anderson NA; Gray S; Copplestone JA; Chan DC; Hamon M; Prentice AG; Johnson SA; Phillips M; van Waeg G; Oakhill A; Abeyasekera S; Pamphilon DH
Transfus Med; 1997 Mar; 7(1):33-9. PubMed ID: 9089983
[TBL] [Abstract][Full Text] [Related]
54. Suitability of measurement of swirling as a marker of platelet shape change in concentrates stored for transfusion.
Mathai J; Resmi KR; Sulochana PV; Sathyabhama S; Baby Saritha G; Krishnan LK
Platelets; 2006 Sep; 17(6):393-6. PubMed ID: 16973500
[TBL] [Abstract][Full Text] [Related]
55. [Effect of leukocyte contamination on storage of platelet concentrates from buffy coats].
Klüter H; Klinger M; Bauhaus M; Kirchner H
Beitr Infusionsther Transfusionsmed; 1994; 32():61-5. PubMed ID: 9480159
[TBL] [Abstract][Full Text] [Related]
56. Quality assessment of platelet concentrates prepared by platelet-rich plasma, buffy-coat, and apheresis methods in a tertiary care hospital in South India: A cross-sectional study.
Toora E; Kulkarni RG; Manivannan P; Sastry AS; Basavarajegowda A; Sahoo D
Asian J Transfus Sci; 2023; 17(2):239-245. PubMed ID: 38274963
[TBL] [Abstract][Full Text] [Related]
57. Circulation and distribution of 111-In-oxine-labeled autologous baboon platelet aggregates and buffy coat.
Valeri CR; Macgregor H; Giorgio A; Ragno G
Transfus Apher Sci; 2005 Apr; 32(2):139-46. PubMed ID: 15784447
[TBL] [Abstract][Full Text] [Related]
58. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF).
Dohan Ehrenfest DM; Rasmusson L; Albrektsson T
Trends Biotechnol; 2009 Mar; 27(3):158-67. PubMed ID: 19187989
[TBL] [Abstract][Full Text] [Related]
59. [Reduction of the platelet transfusion dose and its effects].
Baek EJ; Lee YS; Kim HS; Bae IC; Kim HO
Korean J Lab Med; 2009 Apr; 29(2):158-62. PubMed ID: 19411784
[TBL] [Abstract][Full Text] [Related]
60. Quality assessment and transfusion efficacy of buffy coat-derived platelet concentrates washed with platelet additive solution.
Fernández-Muñoz H; Castilla-Llorente C; Plaza EM; Martínez-Millán C; Heras I; Iniesta P; Amigo ML; Ferrer-Marin F; Candela MJ; Lozano ML; Vicente V; Rivera J
Blood Transfus; 2018 May; 16(3):273-278. PubMed ID: 28488971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
